IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Trial details
- Registry ID
- NCT05155254
- Phase
- Phase 3
The FDA approved Pembrolizumab (KEYTRUDA®) on 4 Sep 2014.
Drug identity checked against registry records
Also recorded as KEYTRUDA®; Keytruda; Keytruda®
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2014-09-04Day | Pembrolizumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125514", "applicant_as_listed_by_fda": "MERCK SHARP DOHME", "brand_names": ["KEYTRUDA"], "active_ingredients": ["PEMBROLIZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20140904", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |